Daniel Lochner

No más puestos en curso

Fortuna: 2 M $ al 31/05/2026

44 años

81 relaciones

Health Technology

Consumer Services

Commercial Services

Perfil

Daniel Lochner is currently Chief Financial Officer at Tectonic Therapeutic, Inc. and Chief Financial Officer at Tectonic Operating Co., Inc., both starting in 2024.
Former positions include Chief Financial Officer at AVROBIO, Inc. in 2024, Chief Financial & Business Officer-Eye Care at Viatris, Inc. from 2023 to 2024, Chief Financial & Business Officer at Oyster Point Pharma, Inc. from 2022 to 2023, and Portfolio Manager at Goldman Sachs Asset Management LP from 2005 to 2019.
Education includes an MBA from The Trustees of Columbia University in The City of New York and an undergraduate degree from the University of Richmond.

Participaciones conocidas en empresas públicas

Empresa	Fecha	Número de acciones	Valoración	Fecha de valoración
0,31 %	11/06/2026	58.544 ( 0,31 % )	2 M $	31/05/2026

Cargos activos de Daniel Lochner

Empresas	Cargo	Inicio
Tectonic Therapeutic, Inc. Tectonic Therapeutic, Inc. Miscellaneous Commercial ServicesCommercial Services Operates biotechnology company that transforming the discovery of novel G-protein-coupled receptors targeted therapies	Director Financiero/CFO	01/06/2024

Todos los cargos activos de Daniel Lochner

Antiguos cargos conocidos de Daniel Lochner.

Empresas	Cargo	Fin
VIATRIS INC.	Corporate Officer/Principal	01/04/2024
OYSR POIN	Director Financiero/CFO	01/01/2023
Goldman Sachs Asset Management LP Goldman Sachs Asset Management LP Investment ManagersFinance GSMALP offers a wide array of investment strategies that span asset classes, industries, and geographies. The firm's products and services across a full range of asset classes including fixed income, money markets, public and private equity, commodities, hedge funds, and real estate. Clients access these solutions through GSAM's proprietary strategies, strategic partnerships, and open architecture programs.	Gestor de Cartera-Acciones	01/07/2019
TECTONIC THERAPEUTIC, INC.	Director Financiero/CFO	-

Ver el detalle de la experiencia de Daniel Lochner.

Formación de Daniel Lochner.

Experiencias
Funciones ocupadas

Activas

Inactivas

Empresas cotizadas

Empresas privadas

Ver el detalle de la experiencia de Daniel Lochner.

Relaciones

Relaciones de 1er grado

Empresas vinculadas al 1er grado

Hombre

Mujer

Administradores

Ejecutivos

Consultar la red personal

Empresas relacionadas

Empresas privadas	7
Goldman Sachs Asset Management LP Goldman Sachs Asset Management LP Investment ManagersFinance GSMALP offers a wide array of investment strategies that span asset classes, industries, and geographies. The firm's products and services across a full range of asset classes including fixed income, money markets, public and private equity, commodities, hedge funds, and real estate. Clients access these solutions through GSAM's proprietary strategies, strategic partnerships, and open architecture programs.	Finance
The Trustees of Columbia University in The City of New York The Trustees of Columbia University in The City of New York Other Consumer ServicesConsumer Services Functions as a College/University	Consumer Services
University of Richmond University of Richmond Other Consumer ServicesConsumer Services Functions as a College/University	Consumer Services
AVROBIO, Inc. AVROBIO, Inc. BiotechnologyHealth Technology Develops potentially curative ex vivo lentiviral-based gene therapies to treat rare diseases in a single dose	Health Technology
Oyster Point Pharma, Inc. Oyster Point Pharma, Inc. Miscellaneous Commercial ServicesCommercial Services Operates as a clinical stage biopharmaceutical company that develops and commercializes pharmaceutical therapies to treat ocular surface diseases	Commercial Services
Viatris, Inc. Viatris, Inc. Pharmaceuticals: MajorHealth Technology Manufactures and wholesales pharmaceutical products	Health Technology
Tectonic Therapeutic, Inc. Tectonic Therapeutic, Inc. Miscellaneous Commercial ServicesCommercial Services Operates biotechnology company that transforming the discovery of novel G-protein-coupled receptors targeted therapies	Commercial Services